acute coronary syndrome | GenomeWeb

acute coronary syndrome

The latest analysis of CYP2C19 genotyping to guide antiplatelet therapy tries to address cost questions from the vantage of a payor or large healthcare system.

The test will be used in a Phase III clinical trial that seeks to validate the clinical efficacy of dalcetrapib.

A study led by researchers from Brigham and Women's Hospital on the effect of CYP2C19 testing on physicians' prescribing patterns has found that when doctors received patient test results for genetic markers associated with clopidogrel response through a pharmacy-benefit manager-

Nanosphere said it has completed data collection in a fast track trial toward submitting its cardiac troponin I assay for FDA approval later this year.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.